JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Letter to the Editor
Contributions of ELN2022 update and new genetic analysis tests in the risk assesment and treatment of acute myeloid leukaemia
Abstract
Acute myeloid leukaemia (AML) is a heterogeneous disease including cytogenetic and molecular abnormalities. Age, performance status and specific genetic characteristics are important in prognosis. Both directing consolidation treatment and having genetic-based treatment targets have made genetic results even more important. The European LeukemiaNet (ELN) 2022 report was published by expanding the genetic mutation profile. In order to question what this update has changed in clinical practice, we reviewed the data of patients with acute myeloid leukaemia in whom myeloid panel was studied by Next-Generation Sequencing (NGS).

Keywords : Acute myeloid leukemia, classifications, next generation sequencing, polymerase chain reaction

Download Article


1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomicclassification and prognosis in acute myeloid leukemia. N Engl J Med.2016;374(23):2209-2221.
2. Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscapeof acute myeloid leukaemia. Nature. 2018;562(7728):526-531.
3. Sekeres MA, Peterson B, Dodge RK, et al. Differences in prognosticfactors and outcomes in African Americans and whites with acutemyeloid leukemia. Blood. 2004;103(11):4036-4042.
4. Olesen LH, Aggerholm A, Andersen BL, et al. Molecular typing ofadult acute myeloid leukaemia: significance of translocations, tandemduplications, methylation, and selective gene expression profiling. Br JHaematol. 2005;131(4):457.
5. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer.2001;92(5):1059.
6. El Chaer F, Hourigan CS, Zeidan AM. How I treat AML incorporatingthe updated classifications and guidelines. Blood. 2023;141(23):2813-2823.
7. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and managementof AML in adults: 2022 recommendations from an international expertpanel on behalf of the ELN. Blood, J Am Soc Hematol. 2022;140(12):1345-1377.
8. Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia,version 3.2019, NCCN clinical practice guidelines in oncology. J NatlCompr Canc Netw. 2019;17(6):721-749.
Article available in :
Volume 2, Issue 1, 2024
Page : 22-23
https://doi.org/10.51271/JCHOR-0031
Article Information
Received : 10 Dec 2023
Accepted : 11 Jan 2024
Published : 12 Feb 2024
Corresponding Author :

Seda Yılmaz: Department of Hematology, Konya City Hospital, Konya, Turkiye

[email protected]
Citation : Yılmaz S, Bağcı M, Baştürk A. Contributions of ELN2022 update and new genetic analysis tests in the risk assesment and treatment of acute myeloid leukaemia. J Curr Hematol Oncol Res. 2024;2(1):22-23.

Read: 619
Download : 654
Cited: 0
_Footer